Mersana Therapeutics Current Ratio 2016-2021 | MRSN

Mersana Therapeutics current ratio from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Mersana Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.23B $0.04B 5.77
2021-03-31 $0.23B $0.04B 6.64
2020-12-31 $0.26B $0.03B 8.62
2020-09-30 $0.28B $0.02B 13.05
2020-06-30 $0.30B $0.02B 13.15
2020-03-31 $0.08B $0.02B 4.59
2019-12-31 $0.10B $0.02B 4.21
2019-09-30 $0.12B $0.02B 5.12
2019-06-30 $0.13B $0.02B 5.50
2019-03-31 $0.14B $0.02B 6.24
2018-12-31 $0.07B $0.07B 1.07
2018-09-30 $0.09B $0.03B 2.86
2018-06-30 $0.10B $0.03B 3.21
2018-03-31 $0.11B $0.03B 3.80
2017-12-31 $0.12B $0.03B 3.69
2017-09-30 $0.14B $0.03B 5.58
2017-06-30 $0.08B $0.03B 2.53
2017-03-31 $0.00B 0.00
2016-12-31 $0.00B 0.00
2016-09-30 $0.00B 0.00
2016-06-30 $0.00B 0.00
2015-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.606B $0.001B
Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76